XML 47 R35.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2020

The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Year Ended December 31, 2020						Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	30,220	$	—	$	30,220	$	29,465	$	—	$	29,465
Research and development revenue	17,886		20,950		38,836		28,691		10,302		38,993
Total revenues	48,106		20,950		69,056		58,156		10,302		68,458
Costs and operating expenses:
Cost of product revenue	13,742		—		13,742		15,632		—		15,632
Research and development (1)	20,923		21,705		42,628		19,380		13,278		32,658
Selling, general and administrative(1)	9,597		2,355		11,952		8,462		2,222		10,684
Total segment costs and operating expenses	44,262		24,060		68,322		43,474		15,500		58,974
Income (loss) from operations	$	3,844	$	(3,110)	734		$	14,682	$	(5,198)	9,484
Corporate costs (2)					(22,306)						(19,624)
Depreciation and amortization					(2,099)						(1,778)
Loss before income taxes					$	(23,671)					$	(11,918)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.


	Year Ended December 31, 2019						Year Ended December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	29,465	$	—	$	29,465	$	25,590	$	—	$	25,590
Research and development revenue	28,691		10,302		38,993		21,483		13,521		35,004
Total revenues	58,156		10,302		68,458		47,073		13,521		60,594
Costs and operating expenses:
Cost of product revenue	15,632		—		15,632		12,620		—		12,620
Research and development (1)	19,380		13,278		32,658		18,924		10,185		29,109
Selling, general and administrative(1)	8,462		2,222		10,684		7,538		771		8,309
Total segment costs and operating expenses	43,474		15,500		58,974		39,082		10,956		50,038
Income (loss) from operations	$	14,682	$	(5,198)	9,484		$	7,991	$	2,565	10,556
Corporate costs (2)					(19,624)						(20,324)
Depreciation					(1,778)						(1,147)
Loss before income taxes					$	(11,918)					$	(10,915)

(1) For the year ended December 31, 2019, research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. For the year ended December 31, 2018, research and development expenses and selling, general and administrative expenses exclude depreciation.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Years Ended December 31,
	2020		2019		2018
Performance Enzymes	$	2,970	$	2,303	$	2,591
Novel Biotherapeutics	768		695		338
Corporate cost	3,990		3,945		4,960
Total	$	7,728	$	6,943	$	7,889

Schedule of Customers That Contributed 10% or More of Total Accounts Receivable

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues For the Years Ended December 31,
	2020		2019		2018
Merck	26	%	28	%	29	%
Nestlé Health Science	11	%	15	%	22	%
Novartis	*		23	%	*
Tate & Lyle	*		*		13	%
Takeda Pharmaceutical Co. Ltd.	19	%	*		*

* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables As Of December 31,
	2020		2019
Merck & Co.	32	%	38	%
Nestlé Health Science	13	%	10	%
Novartis	25	%	*

* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Year Ended December 31, 2020
	2020		2019		2018
Revenues
Americas	$	24,352	$	13,039	$	15,370
EMEA	19,257		37,133		22,361
APAC	25,447		18,286		22,863
Total revenues	$	69,056	$	68,458	$	60,594

Schedule of Long-lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):


	December 31,
	2020		2019
United States	$	31,176	$	30,387

Schedule of Intangible Assets and Goodwill

Identifiable goodwill was as follows (in thousands):`


	Year Ended December 31, 2020						Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241